MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement
Rhea-AI Summary
MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases, has regained compliance with the Nasdaq Capital Market's market value of listed securities (MVLS) requirement. The company received confirmation from NASDAQ on July 23, 2024, that it has satisfied the MVLS requirement as outlined in Nasdaq Listing Rule 5550(b)(2). This development ensures MiNK Therapeutics' continued listing on the NASDAQ Capital Market, and the matter is now considered closed.
Positive
- Regained compliance with Nasdaq Capital Market's MVLS requirement
- Secured continued listing on the NASDAQ Capital Market
Negative
- None.
News Market Reaction – INKT
In the trading session that priced this news, INKT gained 1.72%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced today that it has regained compliance with the Nasdaq Capital Market’s market value of listed securities (“MVLS”) requirement.
On July 23, 2024, MiNK received notice from NASDAQ confirming that the Company has satisfied the MVLS requirement as set forth in Nasdaq Listing Rule 5550(b)(2). Accordingly, the Company now satisfies the MVLS requirement for continued listing on the NASDAQ Capital Market and the matter is now closed.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
Investor Contact
917-362-1370
Media Contact
781-674-4428
communications@minktherapeutics.com
